Systematic review of artesunate pharmacokinetics: implication for treatment of resistant malaria.

03 Sep 2019
Kouakou YI, Tod M, Leboucher G, Lavoignat A, Bonnot G, Bienvenu AL, Picot S

BACKGROUND

Artesunate (ART) is an artemisinin derivative used as monotherapy for the treatment of severe malaria and in combination with a partner drug for non-severe malaria. Resistance of malaria parasites to artemisinins have emerged in Southeast Asia. Adjustment of drug regimen may be an option to prevent therapeutic failures considering the relative favourable safety profile of ART high doses.

METHODS

For that purpose, a systematic review was done using PubMed, Scopus and Web of Science databases. All studies on ART and DHA pharmacokinetic post-administration of artesunate in human patients or volunteers were included. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist 2009 was used.

FINDINGS

Fifty studies exploring oral, intravenous, rectal, and intramuscular route (1470 persons, volunteers and patients) were included. Correlations between artesunate doses and C or AUC of dihydroartemisinin (DHA) and DHA + ART were evaluated. This correlation was good (R > 0·9) using intravenous (IV) route. DHA and ART + DHA average concentrations (Cav) were well above estimated in vivo half-maximal effective concentration (EC) for intravenous route, but this was not the case for oral route.

INTERPRETATION

The favorable Cav/EC ratio for IV route provides an evidence that IV ART will remain efficient even in the case of increased resistance level, whereas for oral route, a two-fold increase in EC may lead to therapeutic failures, thus providing a rationale for oral dose escalation. Considering the inter-individual variability of ART pharmacokinetic, Therapeutic Drug Monitoring through antimalarial stewardship activities is needed to optimize drug exposure and avoid resistance development.